Ono Pharmaceutical Company, Ltd.
93 articles with Ono Pharmaceutical Company, Ltd.
ONO PHARMA USA's Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
ONO PHARMA USA, INC., announced that its candidate, tirabrutinib, a Bruton's tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration for the treatment of patients with primary central nervous system lymphoma.
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
Macomics Ltd announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
Cue Biopharma, Inc. (Nasdaq: CUE) announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics® Platform Technology
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics ® Platform Technology.
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
PrecisionLife Limited, a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases announced that it has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd., an R&D-orientated pharmaceutical company.
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
Equillium grants Ono an option to purchase rights to itolizumab.
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Fate Therapeutics, Inc. announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell product candidate targeting human epidermal growth factor receptor 2 -expressing solid tumors.
Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets
Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd.
ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.
ONO PHARMA USA, INC. announces its organization and leadership team expansion to advance its clinical development, research alliance, licensing activities, as well as future commercialization opportunities for the upcoming products in the U.S.
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017.
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases
Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.
ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.S
ONO PHARMA USA , INC announced the initiation of a Phase 1 study of ONO-4685, an anti-PD-1/CD3 bispecific antibody, in patients with relapsed or refractory T-cell Lymphoma in the U.S.
Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Molecular Profiling Assay Across Several Ono Clinical Studies
Caris Life Sciences® and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris' best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing assay, across several studies beginning later this year.
BioSpace Movers & Shakers, Oct. 1
10/1/2021Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
ONO PHARMA USA, INC. announced the appointment of David Trexler as Chief Commercial Officer of OPUS.
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-239
AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with Ono Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative biopharmaceuticals at the clinical development stage. ONO is a R&D-oriented pharmaceutical company committed to discovering and developin
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy